|
|
||||||||
Guest Access | Sign In via User Name/Password |
|||||||||
University of Adelaide Adelaide, SA, Australia
Correspondence to: Timothy P. Hutchinson, PhD, Centre for Automotive Safety Research, University of Adelaide, Adelaide, SA 5005, Australia; e-mail: paul{at}casr.adelaide.edu.au
To the Editor:
Table 1 , part (a) lists the combinations of melanoma antigen (MAGE) markers giving positive results occurring in 37 lung cancer patients (information from Tables 1 and 2 of the study by Mecklenburg et al1). Unless we are sure the different markers are independent of each other, the dependencies among them may be of interest.
|
It is chance that the lists are the reverse of each other.
As a concise description of the data, Table 1 (part c) is not unique. The positioning of E is ambiguous, as it could be first in the first list and last in the second list.
An alternative analysis might start from part (a) of Table 1 and employ a "positive-implies-positive" rule. This is not successful for this data set, as so many of the markers occur as the only positive result, in one patient or another.
If the lists in part (c) of Table 1 are taken seriously, they might be considered a theory and interpreted as resiliencies of the different MAGE markers, with a patients positions reflecting the strengths of the two systems for suppressing them. I have used the same method of summarizing data in the context of which patients do or do not succeed at various neuropsychological tests,2 and which chemicals do or do not kill various microorganisms.3 Interpretations could be made in terms of systems damaged to lesser or greater degrees, with a rule either saying both components are needed or saying one component is sufficient for a certain outcome. The method has disadvantages, admittedly. It is silent about degrees of response, dealing only with a 0/1 dichotomy, and there is no random element.
Reservations About the Data
Treating Tables 1 and 2 of the study by Mecklenburg et al1 as a single data set is questionable. They refer to induced sputum and BAL fluid, respectively. Moreover, the level of MAGE expression is reported as being much higher in Table 2. It is arguable that marker C should have been excluded from consideration, since it is a conflation of MAGE-3 and MAGE-6 (see page 253 of the article by Kufer et al4). Repeated observations from the same patient are not available, so allowance cannot be made for possible errors.
I hope that part (c) of Table 1 is thought-provoking despite the preceding paragraph, and that the proposed method of summarizing patterns of expression may be useful with other data sets.
Footnotes
Reproduction of this article is prohibited without written permission from the American College of Chest Physicians (e-mail: www.chestjournal.org/misc/reprints.shtml).
References
Ludwig-Maximilians-University Munich, Germany
Correspondence to: Ingo Mecklenburg, MD, Institut für Immunologie, Goethestrasse 31, 80336 Munich, Germany; e-mail: ingo.mecklenburg{at}med.uni-muenchen.de
To the Editor:
We thank Dr. Hutchinson for his detailed statistical review of our described melanoma antigen (MAGE) expression profiles in sputum and bronchial fluid of lung cancer patients.1 We definitely agree to his notion that different MAGE expression patterns need further attention, as the distinct expression of individual markers might have particular prognostic impact or may be used for further subclassification of disease.
However, comprehensive analysis of large cohorts of patients with different types of cancers have not yielded any transparent order of distribution yet. Moreover, the additional quantitative assessment of MAGE expression by real-time polymerase chain reaction displays a rather arbitrary gene activity of individual markers in different types of tumors (unpublished data), and the sensitivity threshold of the utilized assay markedly affects the formation of the expression pattern.
The biological function and the physiologic role of individual cancer/testis antigens is still obscure23; therefore, we are currently tracking prospective data for a correlation of the course of disease with the MAGE expression profile in primary tumor tissue, venous blood, and bone marrow aspirates of cancer patients in several cohorts. Subsequently, a detailed statistical assessment of the data sets has to be done, and the proposed method for summarizing the patterns of MAGE expression may be helpful for the generation of a later decision model. However, far more clinical experience is needed with this approach, and quantitative data will have to be included in the final analysis as relevant carrier of additional information.
References
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |